Skip to main content
Fig. 4 | BMC Pulmonary Medicine

Fig. 4

From: A phase I, randomized, observer-blinded, single and multiple ascending-dose study to investigate the safety, pharmacokinetics, and immunogenicity of BITS7201A, a bispecific antibody targeting IL-13 and IL-17, in healthy volunteers

Fig. 4

Individual subject serum levels of IL-17FF. a Single ascending-dose study (Cohorts A–E). b Multiple ascending-dose study (Cohorts F–H). BITS7201A-treated subjects, closed black symbols; placebo subjects, open gray symbols. Values that fell below the limit of detection of the assay were plotted as half of the minimum quantifiable concentration (MQC). MQC = 6 pg/mL. Some timepoints were not available for certain subjects due to subject withdrawal or loss to follow-up. One subject in Cohort F who received placebo had elevated IL-17FF at baseline and throughout the duration of the study. IL-17FF levels were not assessed in the one patient with mild, atopic asthma in Cohort I

Back to article page

BMC Pulmonary Medicine

ISSN: 1471-2466

Contact us